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Introduction
Type 1 diabetes mellitus (T1DM) is caused by the
autoimmune-mediated destruction of insulin-produc-
ing beta cells in the pancreas. Presently in Europe,
children with T1DM in Europe are treated with insulin
which leads to the good metabolic control, but unfor-
tunately there is no causative cure for this disease.
During the last decade there has been a great progress
in understanding the role of peripheral tolerance break-
down in the pathogenesis of autoimmune diseases. The
most important immunologic defects that occur in
T1DM are related to T lymphocytes. In recent years,
there has been a great deal of interest in developing
immunotherapy approaches to treat T1DM. Those
approaches should include preventing or suppressing
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autoimmune reaction by influencing T lymphocytes.
Autoreactive T cells are normally present in most indi-
viduals and T regulatory cells (Tregs) represent an
active mechanism of suppressing autoreactive T cells
that escape central tolerance. The critical role for reg-
ulatory T cells (Treg) in suppressing autoimmune
pathology is now well recognised [1]. However, the
extent to which defects in regulation can be blamed for
the onset of diseases like type 1 diabetes is not clear.
Since their discovery, extensive research has focused
on phenotype, activation mechanisms and suppressive
function of Tregs, but the precise molecular basis of
these processes in still not known. It also takes a lot of
effort to identify the unique molecules expressed only
on T regulatory cells. In addition to CD25 and FoxP3,
other markers given consideration are: CD103, OX40,
4-1BB, GITR, CTLA-4, PD1 and neuropilin-1
(reviewed in [2]). None of these cell surface markers
appear to be definitive. Transcription factor FoxP3
represents a classical Treg cells marker. Two recent
reports found a strong correlation between FoxP3
expression and down-regulation of IL-7 receptor
(CD127) [3,4]. For functional studies the
CD4+CD25highCD127low cells are considered as T
regulatory cells. The tumor necrosis factor receptor
family members OX40 (CD134) and 4-1BB
(CD137) have been found to play a role in control-
ling the generation and activity of T regulatory cells
(reviewed in [5]). The activation, expansion, and
survival of regulatory T cells as well as the expres-
sion of their suppressive capacities result from dis-
tinct signaling pathways involving various mem-
brane receptors and cytokines. Previously, it was
concluded that naturally occurring Treg cells medi-
ate suppression in a cell contact dependent, a
cytokine-independent mechanism. However, it is
highly likely that the suppression mechanisms of
Tregs can be divided into: suppression by inhibitory
cytokines, suppression by cytolysis, suppression by
metabolic disruption and suppression by modulation
of dendritic cells (reviewed in [2]). Recently it has
been demonstrated that Tregs are able to mediate
suppression across a permeable membrane [6]. This
phenomenon was mediated by IL-35 and IL-10. The
contribution of Treg-derived cytokines in autoimmu-
nity remains controversial but it is possible that T
regulatory cell-derived cytokines can suppress Th1
and/or Th2-type responses and in this manner influ-
ence the immune balance. Additionally, it was
demonstrated that Tregs have cytolytic capacity and
granzyme/perforin pathways are required for this
activity [7]. 
The experimental and clinical aspects of the role of
Tregs in the pathogenesis of T1DM have been inten-
sively discussed (reviews in [8] and [9]). Most of the
tests were performed on animal models including non-
obese diabetic mice (NOD mice) and they report quan-
titative and/or qualitative disturbances in T regulatory
cells as a crucial factor for development or cure of
autoimmune diabetes.  However, several fundamen-
tal questions concerning the role of Treg cells in the
T1DM pathogenesis remain unanswered e.g. previ-
ous studies concerned CD4+CD25+ not CD127low
cells, due to methodological problems only few mol-
ecules/cytokines in one sample were assessed etc.
Results from other laboratories and our preliminary
experiments suggest that T regulatory cells produce
cytokines in human organism but the knowledge in
this field is poor. The aim of our study was to test the
hypothesis that T regulatory cells express pro- and
anti-inflammatory cytokines, elements of cytotoxicity
and OX40/4-1BB molecules. In the CD4+
CD25+CD127dim/- cells separated from the peripheral
blood of children with type 1 diabetes and healthy sub-
jects we found mRNA for TGF-β, IL-2, IL-4, IL-10,
TNF-α, OX40, 4-1BB, perforin 1 but not granzyme B. 
Materials and methods
Patients. The examined group consisted of 50 children with
T1DM. Fifty two healthy individuals (control group) were enrolled
into the study. The subjects from the control group had no signs of
autoimmune, chronic, inflammatory, neoplasmatic disease and had
negative family history for T1DM (no differences in sex and age
compared to the examined group, p>0.05), these children did not
receive any drugs. Type 1 diabetes in the examined group was
diagnosed according to the American Diabetes Association criteria
[10]. The mean age of children with T1DM was 10.4±3.9 compar-
ing to the controls: 11.0±3.7, the mean insulin intake at the moment
of blood collection in examined group was 0.9 U/kg/day, in control
subjects – 0. All examined patients were treated only with insulin
(intensive regimen), no other drugs were administered in this
group. Only children with good clinical status at the admittance to
the hospital and no presence of allergy and/or infection or any
other chronic disease were enrolled into the study. The peripheral
blood was collected after achieving the metabolic balance, 24 to 35
days from the diagnosis/start of insulin treatment.  The blood were
obtained samples from the patients and controls under the proto-
cols approved by the Medical University of Bialystok institutional
review board. An informed consent was given by the participating
children and their parents.
Flow cytometry. Mononuclear cells were isolated on Ficoll densi-
ty gradients. A flow cytometric analysis of T-cell subpopulations
was performed using the following markers: anti-CD3 (phycoery-
thrin-cyanin 5 PECy5 conjugated, UCHT1 clone), anti-CD4 (phy-
coerythrin-cyanin 7 PECy7 conjugated, SFCI12T4D11 clone or
phycoerythrin-cyanin 5 PECy5 conjugated, UCHT1 clone), anti-
CD25 (fluorescein isothiocyanate FITC conjugated, B1.49.9 clone
or ECD conjugated, B1.49.9 clone), anti-CD127 (=IL-7R, phyco-
erythrin conjugated PE, R34.34 clone), anti-CD134 (=OX40, PE,
Ber-ACT35 clone or FITC, ACT35) and anti-CD137 (=4-1BB, PE
conjugated, C65-485) purchased from Beckman Coulter and Bec-
ton Dickinson (USA). Respective isotype control antibodies were
used. The samples were analysed by five-colour flow cytometer
Beckman Cytomics FC 500 MPL using CXP software ver 2.0
(Beckman Coulter, USA). A minimum of 105 events was aquired
for each analysis. The percentages of positive cells were calculat-
ed. To determine absolute cell counts, a small volume of blood was
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analyzed for complete blood count (CBC) with a differential. The
absolute counts were determined by multiplying the frequency of
positive cells determined in cytometric analysis by the number of
lymphocytes [G/l] as determined by CBC. 
Cell separation. T regulatory cells were isolated from mononu-
clear cells according to the producer instruction (Miltenyi Biotec,
Germany). Briefly, the isolation was performed in a two-step pro-
cedure. Firstly, non-CD4+ and CD127high cells were indirectly
magnetically labelled with a cocktail of antibodies and beads. The
labeled cells were subsequently depleted by separation over a
MACS column. Secondly, CD4+CD25+CD127dim/- cells were
directly labelled with the beads and isolated by positive selection
from pre-enriched CD4+ fraction. To increase the purity, the cells
were separated over a second (new) column.
RNA extraction and  cDNA synthesis. A total RNA from T regu-
latory cells (CD4+CD25+CD127dim/-) was isolated and purified
using Rneasy Mini Kit (Qiagen) following the manufacturer's pro-
tocol. RNA integrity was verified by 1.5% agarose gel elec-
trophoresis/ethidinum bromide staining and OD 260/280 absorption
ratio >1.95. One microgram of total RNA was used to prepare
cDNA. cDNA synthesis was performed using SuperScriptTM First-
Strand Synthesis System for RT-PCR (Invitrogen) according to
manufacturer's instructions in the MJ Research Thermal Cycler
(Model PTC-200, Watertown, MA, USA). 
Real-time RT-PCR. mRNA levels for transcription factor FoxP3,
pro- and  anti-inflammatory cytokines (interferon gamma, inter-
leukin-2, interleukin-4, interleukin-10, transforming growth factor
β1 and tumor necrosis factor α), activatory molecules
(OX40=CD134, 4-1BB=CD137) and elements of cytotoxicity
(granzyme B, perforin 1) were determined by  real-time PCR tech-
nique with the TaqMan chemistry using ready-to-use Low Density
Arrays for Gene Expression by Applied Biosystems
(www.appliedbiosystems.com). It contained target-specific
primers and probe and TaqMan Universal Master Mix, containing
AmpErase uracil-N-glycosylase (UNG) to prevent the re-amplifi-
cation of carryover PCR products. The PCR amplification and flu-
orescence data collection were performed with ABI PRISM
7900HT Sequence Detection System (Applied Biosystems). To
normalize the amount of expressed molecules mRNA, the internal
housekeping gene GAPDH was used and each complementary
DNA (cDNA) product was tested in quadruplicates for each of the
molecules mRNA and GAPDH mRNA. To calculate our data we
used Comparative Ct method for relative quantification (ΔΔCt
method) which describes the change in expression of the target
gene in a test sample relative to a calibrator sample and provides
accurate comparison between the initial level of template in each
sample [11]. Data were analyzed with Sequence Detector System
(SDS) software version 2.1 (Applied Biosystems). 
Statistical analysis. The results from flow cytometry and real-time
RT PCR were entered into the database in Microsoft Access 2007
and after the completion transferred and analysed in Statistica 8.0
for Windows (StatSoft, Poland) and GraphPad Prism 5.0
(GraphPad Software, USA). Due to asymmetric data distribution
(Kolmogorov-Smirnov and Shapiro-Wilk tests) non-parametric
tests were used. The results in the examined and control group
were compared using Mann-Whitney U-test. The correlation
between the clinical parameters and flow cytometry/real time PCR
results were assessed with Spearman's Rank Correlation Test. P-
values less than 0.05 were considered as significant. The graphs
were prepared in GraphPad Prism 5.0. The data are presented as
median in the results section and median and 25th and 75th per-
centile in figures.
Results
No alterations in the frequency of
CD4+CD25highCD127low cells between diabetic
and control children
The absolute count of white blood cells and lympho-
cytes in the peripheral blood was similar in both exam-
ined and control groups (differences statistically not
significant, data not shown). The percentages of
CD4+CD25highCD127low cells in the peripheral blood
of examined children were very low and did not differ
between diabetic and control groups: 0.59% (0.30-
0.80) vs. 0.55% (0.26-0.97) respectively (p=0.95). In a
small series of patients (n=10) the peripheral blood
was also taken at the admittance to the hospital (day 0).
We found no differences in the percentages of assessed
cell populations between day 0 and day of the sched-
uled assessment of Tregs in children with diabetes
(data not shown). 
The CD4+CD25+CD127dim/- cells express mRNA
for pro- and anti-inflammatory cytokines
Concurrently with the flow cytometric assessment of
Tregs we separated CD4+CD25+CD127dim/- cells for
further mRNA analysis. FoxP3, IFN-γ, IL-2, IL-4, IL-
10, TNF-α, TGF-β1, OX40, 4-1BB and perforin
mRNA presence was confirmed in 100% of separated
CD4+CD25+CD127dim/- cells in both control and dia-
betic children. mRNA for granzyme B was not detect-
ed in any of our cell samples. The samples did not dif-
fer in mRNA levels of transcription factor Foxp3
between the diabetic and control groups (383 vs. 329
respectively, p>0.05). Similarly, the mRNA amounts
for cytokines: IFN-γ, IL-10, IL-2 and TNF-α did not
alter in diabetic children compared to the healthy sub-
jects (505.4 vs. 555.8, 218.2 vs. 222.3, 1146 vs. 1577
and 3.70 vs. 2.96 respectively, p>0.05). Interestingly,
the expression of mRNA for perforin and TGF-β1 were
higher in examined group in comparison to the con-
trols (17.71 vs. 10.39, p=0.006; 2.45 vs. 1.74,
p<0.0001, respectively). The summary of the results
obtained from real-time PCR are depicted in Figure 1.
Lower OX40 and higher 4-1BB mRNA but not
protein levels in CD4+CD25+CD127dim/- cells 
in diabetic patients compared to the healthy
children
The example of the results obtained from flow cytom-
etry is shown in Figure 2. We did not find the differ-
ences in the percentages of CD4+CD25highCD127low
CD134+ and CD4+CD25highCD137+ cells between
examined groups (control vs. diabetic: 0.1 vs. 0.09%
and 0.55 vs. 0.50% respectively, p>0.05) – see Figure
3. However, the level of mRNA for OX40 was lower
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in Treg cells of children with T1DM when compared
to the reference patients (31.26 vs. 44.17, p=0.0001).
The 4-1BB expression tended to be higher in diabetic
children compared with control subjects but the differ-
ence was not statistically significant (173.8 vs. 131.5,
p=0.1). 
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Fig. 1. mRNA expression analysis of chosen genes in CD4+CD25+CD127dim/- cells in children with type 1 diabetes and healthy sub-
jects. Data are presented as median and 25th-75th percentile. The results from real-time PCR showed: higher mRNA levels of perforin
and TGF-β1, lower amounts of mRNA for OX40 and no differences in IFN-γ, IL-10, IL-2 and TNF-α expression in separated cells from
peripheral blood of children with diabetes compared to control children. Additionally, 4-1BB mRNA expression tended to be higher in
examined group but the difference was not statistically significant.
Discussion
To test the hypothesis that T regulatory cells produce
pro- and anti-inflammatory cytokines we separated
CD4+CD25+CD127dim/- cells from the peripheral
blood of healthy and diabetic children. We found the
mRNA expression not only for TGF-β, IL-10 but also
for IFN-γ, IL-2, IL-4 and TNF-α. Numerous studies
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Fig. 2. The example of flow cytometry result showing the percentages of T cell subsets i.e.: CD4+, CD4+CD25high, CD4+CD25highCD134+ and
CD4+CD25highCD137+ cells. Peripheral blood mononuclear cells were stained with anti-CD4, anti-CD25, anti-CD134 and anti-CD137 anti-
bodies and analyzed by Beckman Cytomics FC 500 MPL. The results are shown as the percentages from total lymphocyte population.
Fig. 3. Frequency of CD4+CD25highCD134+ and CD4+CD25highCD137+ cells in the control and diabetic patients. Data are presented as
scatter plots, median and 25th-75th percentile.
over the past few years have demonstrated the impor-
tance of naturally occurring CD4+ CD25+FoxP3+ reg-
ulatory T cells in autoimmune diabetes. To date, results
obtained from these experiments are contradictory.
Most studies performed on human showed no differ-
ences in the percentages of T regulatory cells between
diabetic and healthy subjects. These experiments
included the CD4+CD25highCD127low and CD4+
CD25highFoxP3+ cells [3, 12]. Our results showing
similar percentages of Tregs cells and FoxP3 expres-
sion in diabetic and control children are in harmony
with these findings. Recently, there has been also a
great scientific discussion concerning the methodolog-
ical approach for separating T regulatory cells. Previ-
ously CD4+CD25+ or CD4+CD25high cells were sepa-
rated for functional evaluation. After few reports
which showed that T regulatory cells present down-
regulation of IL-7 receptor (CD127) we chose a novel
kit from Miltenyi Biotec for separation of
CD4+CD25+CD127dim/- cells for mRNA analysis. This
method allows to assess expression of many genes in
one small sample. On the other hand, our results are
difficult to compare with the results obtained by other
authors.
Our results demonstrated higher expression of
mRNA for TGF-β in Tregs separated from diabetic
children compared to control subjects. The observa-
tions of other authors show an important role of TGF-
β and IL-10 production as mediators of Treg activity.
The belief that Tregs act in a contact-dependent,
cytokine-independent manner was based on studies
performed with the use of permeable membrane.
Recently Collison et al. showed that the induction of
suppression of Tregs was contact-dependent but the
function of Tregs was mediated by cytokines: IL-35
and IL-10 [6]. These results raise the possibility of IL-
10 and IL-35 cooperation for achieving the Treg sup-
pressive activity. It is also possible that pro- and anti-
inflammatory cytokines produced by T regulatory cells
interfere with Th1/Th2 polarization towards antigen
presenting cells. One of these cytokines is probably
TGF-β [13].
A novel type of T regulatory cells which possesses
a FoxP3+CD4+CD8+CD25+ phenotype activated by
IL-2 produces high levels of IL-10 [14]. These cells
have also cytotoxic activities. This may be a newly dis-
covered, additional regulatory mechanism. However
mRNA samples in our experiment were CD8+ nega-
tive. In another study the percentages of T cells (CD3+)
producing IL-10 were higher in the peripheral blood of
patients with T1DM than in healthy individuals [15].
Surprisingly, we also found in Tregs the mRNA for
pro-inflammatory cytokines such as IFN-γ, IL-2 and
TNF-α. Interferon gamma can have diverse functions,
it mainly induces proinflammatory Th1-type respons-
es, but also enables T regulatory-type activation. 
IFN-γ is produced by Tregs and plays a crucial role in
their function (reviewed in [16]). Some authors found
a strong correlation between expression of FoxP3 and
IFN-γ in CD4+CD25+ cells for example in patients
after kidney transplantation [17]. In contrast to our
observations absence of IFN-γ production was found
in CD4+CD25highCD39+ T regulatory cells in patients
with active tuberculosis [18]. Lindley et al. did not
observe any differences between diabetic and healthy
subjects in the production of IFN-γ and IL-10 by
CD4+CD25+ subpopulations between diabetic and
healthy subjects [19]. IL-2 provides important signals
for Treg cells development and for their homeostasis in
peripheral immune tissues. IL-2 is also essential for
the survival of mature Foxp3+ regulatory T cells. How-
ever, Tregs, are not sure to be the source of this
cytokine [20]. 
It is also possible, as suggested by Collison et al.,
that interactions between Tregs and other elements of
immune response can be mediated by bidirectional:
contact- and cytokine-dependent signals [6]. On the
other hand a newly discovered subset of T helper cells,
Th17 is thought to play a key role in autoimmunity,
orchestrating tissue inflammation, with IL-17 and IL-
22 as effector cytokines. Based on several observa-
tions including their own Awasthi et al. proposed a
model of the relation between Tregs and Th17 cells
[21]. The most interesting information is that addition
of IL-6 to Treg cells convert them into Th17 cells. The
presence of proinflammatory cytokines confirmed in
our CD4+CD25+CD127dim/- samples can represent
additional link between Th17 and Treg cells, but this
relation is not clear and requires further research. 
Most authors agree that OX40 inhibits the suppres-
sive activity of T regulatory cells [5, 22-24]. Earlier
reports indicated only minimal influence of 4-1BB/4-
1BBL pathway on the proliferation of Tregs but also
noted an essential role in their suppressive function
[22]. In two series of experiments OX40 signaling
inhibited FoxP3 expression and was regarded as antag-
onist of T regulatory cells [23,24]. Additionally
patients with another autoimmune disease – multiple
sclerosis (MS) had lower CD137 expression in Tregs
compared with healthy controls [25]. The plasma lev-
els of soluble CD137 were higher in the group with
MS than in healthy subjects. The impaired 4-1BB
mRNA expression found in our Treg samples can be
one of the mechanisms of their dysfunction. In anoth-
er interesting study Tregs showed up-regulation of the
4-1BB expression in response to IL-2 and soluble 4-
1BB ligand [26]. Additionally treatment with anti-
CD137 protected NOD mice from diabetes [27]. This
phenomenon was probably mediated by T regulatory
cells. 
The cytotoxicity, cell contact-independent mecha-
nism including granzyme/perforin may represent one
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of the pathways by which Tregs can induce long-last-
ing suppression of autoimmune diseases. Little is
known about the expression of granzyme/perforin in
Treg cells in patients with autoimmune diabetes. One
report showed enhancement of T regulatory cell func-
tion including FoxP3 and granzyme B expression by
complete Freund's adjuvant (CFA) therapy in non-
obese diabetic mice [28]. In another study the differ-
ences in the mRNA expression of perforin between
control and diabetic patients were not significant, how-
ever, according to Gondek et al. the contact-mediated
suppression of Tregs is not perforin-dependent [29].
We did not find the mRNA for granzyme B in human
Tregs. According to Cao et al. granzyme B is not
expressed in naive Tregs but can be found in Tregs
present in tumor environment in mice [7]. Some stud-
ies concerning cytotoxic function of Tregs were per-
formed in another autoimmune and neoplasmatic dis-
eases. For example our results concerning low/nega-
tive expression of granzyme B are in agreement with
recent findings in human ulcerative colitis and some
neoplasmatic diseases [30]. 
Our results and other authors' observations confirm
the presence of mRNA for pro- and anti-inflammatory
cytokines in CD4+CD25+CD127dim/- cells in the
peripheral blood of children with T1DM. Further stud-
ies with the goal of developing new strategies to poten-
tiate Treg function in autoimmune diseases are war-
ranted. It would be also of clinical significance if Treg
cells were used not only in a autoimmune-prone indi-
viduals but also in established disease like newly
recognised diabetes.
Conclusions
We found mRNA for pro- and anti-inflammatory
cytokines in CD4+CD25+CD127dim/- cells in the
peripheral blood of children with type 1 diabetes. We
also observed lower mRNA expression for OX40 in
these cells but not at protein level compared to healthy
children.
Perhaps the best approach for immunotherapeutic
intervention in T1DM is to identify and expand anti-
gen-specific Tregs and re-infuse these cells into the
patient. If this approach is to be introduced, the func-
tion of Tregs in autoimmune diseases should be eluci-
dated. Our and other authors' findings add some sup-
plementary information to a debate about preclinical
studies concerning T regulatory cells in autoimmune
diseases. Further examination of the role of cytokine
production and expression of OX40 and 4-1BB by
Treg cells in diabetes might be warranted. 
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